The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle ...

Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...

All parents will now be offered spinal muscular atrophy screening for their newborns.

Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...

Researchers have made a significant finding in determining the genetic background of dilated cardiomyopathy in Dobermanns. This research helps us understand the genetic risk factors related to fatal ...

For decades, treatment of peripheral artery disease has focused almost exclusively on restoring blood flow. Now, new research ...